Korro Bio Announces Major Restructuring and Program Shifts
Korro Bio is focusing on new genetic medicines (GalNAc programs) after poor trial results for KRRO-110, pausing its Novo Nordisk partnership, and reducing its staff by 34%.
/ 44 items
#NVO↓
Novo Nordisk Shares Jump 3% After Withdrawing from $10 Billion Metsera Bidding War
Novo Nordisk stock climbed up to 3% after the Danish drugmaker withdrew from its heated bidding war with Pfizer over obesity drug startup Metsera, citing financial discipline concerns.
Novo Nordisk Raises Bid Again for Metsera as Takeover Battle with Pfizer Heats Up
Novo Nordisk boosts its offer for obesity startup Metsera, countering Pfizer’s $86.20 per share bid. The bidding war is nearing its end as both pharma giants race to dominate the booming obesity drug market.
Trump Slashes Obesity Drug Prices with Lilly, Novo Nordisk Deals
President Trump announced deals with Eli Lilly and Novo Nordisk to slash GLP-1 obesity drug prices for Medicare/Medicaid and launch TrumpRx.gov. Medicare coverage for these costly treatments begins mid-2026.
FTC Warns Novo Nordisk Over Potential Violation in Metsera Bid
The U.S. Federal Trade Commission cautioned Novo Nordisk that its proposed acquisition of Metsera may breach premerger review laws under the Hart-Scott-Rodino Act.
Novo Nordisk Cuts Forecast Amid Growing Competition
Novo Nordisk (NVO) lowers 2025 guidance for the fourth time as Wegovy and Ozempic sales slow. New CEO battles Eli Lilly competition while pursuing $10B Metsera acquisition.